Cash for flow

By applying mass spectroscopy to flow cytometry, DVS Sciences Inc. created a "mass cytometer" that could offer drug developers an efficient way of studying intracellular networks and disease state transitions. The company's first round of VC funding last week will be used to scale up production of the CyTOF instrument and begin commercialization.

Investors in the $14.6 million series A round included 5AM Ventures; Pfizer Venture Investments; Mohr Davidow; Roche Venture Fund; and the Ontario Institute for Cancer Research...